Study of the phase I and phase II metabolism of nephrotoxin aristolochic acid by liquid chromatography/tandem mass spectrometry

被引:85
作者
Chan, Wan
Cui, Liang
Xu, Guowang
Cai, Zongwei [1 ]
机构
[1] Hong Kong Baptist Univ, Dept Chem, Kowloon, Hong Kong, Peoples R China
[2] Chinese Acad Sci, Dalian Inst Chem Phys, Natl Chromatog R&A Ctr, Dalian 116023, Peoples R China
关键词
D O I
10.1002/rcm.2513
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Prolonged exposure to aristolochic acid (AA) was shown to pose rapid progressive renal fibrosis in Belgian women in a slimming regime in the early 1990s. AA was also demonstrated to be strong carcinogen in rats. The carcinogenicity of AA is generally believed to be related to the nitro-reduction of AA, in which the aristolactam-nitriumion ion with a delocalized positive charge is the ultimate carcinogen. In this study, the phase I and phase II metabolism of AA was investigated by using an in vitro system with rat liver S9 and an in vivo animal study with Sprague-Dawley rats. AA was found to have been undergone hydroxylation, lactam formation, and desnitro and desmethyl transformations. Three conjugated metabolites of AA, namely the N- and O-glucuronides of aristolactams, were detected directly in pre-concentrated urine sample, with no acid hydrolysis or enzymatic digestion. Structural elucidation of the metabolites was performed by using liquid chromatography/tandem mass spectrometry (LC/MS/MS). The results indicated that N-glucuronidation was the major phase II metabolic pathway for the aristolactams formed by AA after their nitro-reduction. Copyright (c) 2006 John Wiley & Sons, Ltd.
引用
收藏
页码:1755 / 1760
页数:6
相关论文
共 22 条
  • [1] AKASU M, 1974, TETRAHEDRON LETT, P3609
  • [2] Aristolochic acid as a probable human cancer hazard in herbal remedies: a review
    Arlt, VM
    Stiborova, M
    Schmeiser, HH
    [J]. MUTAGENESIS, 2002, 17 (04) : 265 - 277
  • [3] P-32-post-labelling analysis of DNA adducts formed by aristolochic acid in tissues from patients with Chinese herbs nephropathy
    Bieler, CA
    Stiborova, M
    Wiessler, M
    Cosyns, JP
    deStrihou, CV
    Schmeiser, HH
    [J]. CARCINOGENESIS, 1997, 18 (05) : 1063 - 1067
  • [4] Bourland JA, 1998, DRUG METAB DISPOS, V26, P203
  • [5] Liquid chromatography-electrospray ionization mass spectrometry for metabolism and pharmacokinetic studies of ginsenoside Rg3
    Cai, ZW
    Qian, TX
    Wong, RNS
    Jiang, ZH
    [J]. ANALYTICA CHIMICA ACTA, 2003, 492 (1-2) : 283 - 293
  • [6] Debelle FD, 2002, J AM SOC NEPHROL, V13, P431, DOI 10.1681/ASN.V132431
  • [7] N-glucuronidation of some 4-arylalkyl-1H-imidazoles by rat, dog, and human liver microsomes
    Kaivosaari, S
    Salonen, JS
    Taskinen, J
    [J]. DRUG METABOLISM AND DISPOSITION, 2002, 30 (03) : 295 - 300
  • [8] STUDIES ON THE METABOLISM OF ARISTOLOCHIC ACID-I AND ACID-II
    KRUMBIEGEL, G
    HALLENSLEBEN, J
    MENNICKE, WH
    RITTMANN, N
    ROTH, HJ
    [J]. XENOBIOTICA, 1987, 17 (08) : 981 - 991
  • [9] TUMOR INHIBITORS .1. ARISTOLOCHIC ACID, ACTIVE PRINCIPLE OF ARISTOLOCHIA INDICA
    KUPCHAN, SM
    DOSKOTCH, RW
    [J]. JOURNAL OF MEDICINAL & PHARMACEUTICAL CHEMISTRY, 1962, 5 (03): : 657 - &
  • [10] TUMOR-INDUCTION IN MICE FOLLOWING EXPOSURE TO ARISTOLOCHIC ACID
    MENGS, U
    [J]. ARCHIVES OF TOXICOLOGY, 1988, 61 (06) : 504 - 505